Biocon Biologics' Johor Bahru Site Classified as Voluntary Action Indicated (VAI) by U.S. FDA

Biocon Biologics' Insulins facilities in Johor Bahru, Malaysia have been classified as Voluntary Action Indicated (VAI) by the U.S. Food and Drug Administration (FDA). This classification is based on the cGMP inspection conducted by the agency between September 15 —-27, 2024. The inspection scope included several biologics manufacturing units, laboratories, and warehouses. Biocon Biologics remains committed to global standards of Quality and Compliance.